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Abstract Local excision is increasingly performed for
‘‘early stage’’ rectal cancer in the US; however, local
recurrence after local excision has become a controversial
issue in Western countries. Local recurrence is considered
to originate based on the type of tumor and procedure
performed, and in surgical margin-positive cases. This
review focuses on the inclusion criteria of ‘‘early’’ rectal
cancers for local excision from the Western and Japanese
points of view. ‘‘Early’’ rectal cancer is defined as T1
cancer in the rectum. Only the tumor grade and depth of
invasion are the ‘‘high risk’’ factors which can be evaluated
before treatment. T1 cancers with sm1 or submucosal
invasion \1,000 lm are considered to be ‘‘low risk’’
tumors with less than 3.2 % nodal involvement, and are
considered to be candidates for local excision as the sole
curative surgery. Tumors with a poor tumor grade should
be excluded from local excision. Digital examination,
endoscopy or proctoscopy with biopsy, a barium enema
study and endorectal ultrasonography are useful for iden-
tifying ‘‘low risk’’ or excluding ‘‘high risk’’ factors pre-
operatively for a comprehensive diagnosis. The selection of
an initial local treatment modality is also considered to be
important according to the analysis of the nodal involve-
ment rate after initial local treatment and after radical
surgery.
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Introduction
Local excision was performed in 5.9 % of the 13,434
patients with rectal cancer in the Swedish rectal cancer
registry from 1995 to 2003, and the proportion of local
excision in various procedures remained constant during
that period [1]. Local excision was performed in 12.0 % of
2,131 patients with stage 1 (T1 and T2, N0, M0 [2]) rectal
cancer in this registry from 1995 to 2001 [3]. On the other
hand, the use of local excision increased in patients with
stage 1 rectal cancer from 1989 to 2003 according to the
National Cancer Database in the US [4]. Local excision
was performed in a significantly higher proportion of
patients with T1 lesions (37.9 %) than T2 lesions (12 %)
during the period studied. The rate of local excision sig-
nificantly increased, both for T1 lesions (26.6 % in 1989
vs. 43.7 % in 2003) and T2 lesions (5.8 % in 1989 vs.
16.8 % in 2003) [4].
Local excision is a procedure which can eliminate def-
ecation, sexual and urinary dysfunction and the risk of a
permanent stoma, with a shorter hospital stay and minimal
mortality and morbidity because it avoids radical surgery
[4–6]. However, due to the significant risk of local recur-
rence and a poorer prognosis after local excision compared
with radical resection, its use and indications have recently
become highly debated issues [4–11]. The key to poten-
tially curative local treatment for rectal cancer is to select a
suitable patient or tumor for local excision and to choose
the most suitable local excision procedure. This review
focuses on the inclusion criteria for ‘‘early’’ rectal cancers
for local excision from the Western and Japanese points of
view.
A literature review was undertaken using the MEDLINE
database for the English literature and the Igaku Chuo
Zasshi for the Japanese literature, and by cross-referencing
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previous publications. The appropriate publications were
selected and cited for the review. The following key words
were used for the searches: early rectal cancer, T1 rectal
cancer, T2 rectal cancer, stage 1 cancer, local excision and
local treatment.
Definition of ‘‘early’’ rectal cancer and the rectum
in Japan and Western countries
Rectal cancer has been defined as a cancerous lesion located
within 12 cm of the anal verge by rigid proctoscopy in US
[12, 13]. On the other hand, tumors with distal extension to
\15 cm (as measured by rigid sigmoidoscopy) from the
anal margin are classified as rectal, while more proximal
tumors are classified as colonic in the ESMO guidelines
[14]. The rectum is divided into two parts in Japan; the
rectum above and below the peritoneal reflection, and the
upper limit of the rectum above the peritoneal reflection is
the lower end of the second sacral bone [15]. Therefore, the
definition of the rectum differs according to the guidelines,
rules and countries studied. However, the definition of the
rectum itself is not considered to dramatically affect the
outcomes of local excision for ‘‘early’’ rectal cancer, which
is going to be discussed here, although it might be associ-
ated with the specific procedure adopted for local excision
and the outcomes of more advanced rectal cancers.
T1 and T2 rectal cancers according to the tumor node
metastasis classification (TMN) [2] have been reported as
‘‘early’’ [9, 16, 17] or ‘‘early stage’’ [18, 19] cancer in
many Western publications. On the other hand, Tis and T1
cancers of the rectum have been considered as ‘‘early’’
cancer [15] in accordance with the Japanese classification
of gastric cancer [20]. In the ESMO clinical practice
guidelines [14], rectal cancer is divided into four groups:
very early (some cT1), early (cT1–2, some cT3), more
advanced (cT3, some cT4) and locally advanced (cT4).
Neoplastic cells, when confined to the colorectal mucosa,
are correctly defined as dysplasia or adenoma in the UK,
and the misnomers ‘‘intramucosal carcinoma’’ and ‘‘carci-
noma in situ’’ are used in the US and Japanese literature
[7]. Tytherleigh et al. [7] defined early rectal cancer as
invasive adenocarcinoma spreading into, but not beyond,
the submucosa; that is, a T1 tumor in the TNM classifi-
cation according to Morson’s definition [21]. This defini-
tion was used in several papers [22–24] and is adopted in
this article as the proper definition of ‘‘early’’ rectal cancer.
Stage 1 in the TNM classification includes T1 and T2
tumors with N0 and M0. It is currently impossible to cor-
rectly diagnose lymph node metastasis perioperatively
when performing local excision [5, 7]. Therefore, T1 and
T2 rectal cancers are both considered to be ‘‘early stage’’
rectal cancer in this article.
Frequency of T1 and T2 tumors
Stage 1 (T1 and T2, N0, M0) rectal cancer comprises 20-
34 % of all rectal cancers [3, 25–27]. Among the 35,179
patients with stage 1 cancer treated from 1989 to 2002 in
the US, T1 lesions were identified in 43.8 % and T2 in
56.2 % of the patients [4]. Among 2,177 patients under-
going bowel resection for T1 and T2 lesions from 1995 to
1998 in Japan, T1 lesions were identified in 36.7 % of the
cases [25]. The incidence of T1 lesions removed by
endoscopic polypectomy in Japan rose from 3.8 % in 1978
to 10.3 % in 1997 [28]. Three to 8.6 % of all resected
colorectal adenocarcinomas are reported to be T1 lesions in
Western countries [16, 21, 29, 30], 3.6 % in Korea [31] and
12.1 % in Japan [25]. Tytherleigh and Mortensen et al. [7]
stated that the incidence of early rectal cancer (T1 cancer)
will likely rise following the start of the UK screening
program. When considering the results of a national survey
showing that colorectal cancers found at the time of
screening are mostly early-stage cancers; with 45.3 %
being cancer in situ, 20 % being T1 cancer and 11.1 %
being T2 cancer [32], the number of ‘‘early’’ cancers is
expected to increase not only in Japan, but also worldwide.
Subclassification of T1 cancer
Haggitt’s subclassification [33] is most commonly used for
polypoid T1 cancers or malignant rectal polyps (T1 cancer)
in Western countries [13, 14]. It is based upon the extent of
invasion of the stalk and is divided into five levels; 0: the
absence of invasive carcinoma, 1: invasion into the head of
the polyp, 2: invasion into the neck, 3: invasion into the
stalk, 4: invasion into the base [33]. The subclassification
of T1 cancers based upon the depth of invasion into the
submucosal layer is also used for sessile-type tumors in
both Japan [22, 34] and Western countries [14, 34]. In this
subclassification, the submucosal layer is divided into three
layers according to the depth of invasion; the 1: upper
third, 2: middle third and 3: lower third [34]. The ESMO
clinical practice guidelines [14] add that Haggitt’s levels
1–3 correspond to sm1, and level 4 may be sm1–3. Mea-
surement of the depth of invasion into the submucosal layer
is recommended by the General Rules for Clinical and
Pathological Studies on Cancer of the Colon, Rectum and
Anus in Japan [15], and additional bowel resection is rec-
ommended based on the distance of invasion into the
submucosal layer after local treatment [25]. The term sm
‘‘scant’’ or ‘‘slight’’ is sometimes used as a term corre-
sponding to sm1, and sm ‘‘massive’’ as sm3 (sometimes
including sm2) in Japan. Very early cancer (some cT1) in
the ESMO guidelines is considered to correspond to sm
‘‘scant’’ or ‘‘slight’’ T1 cancer (sm1) in Japan.
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‘‘Risk factors’’ for T1 cancers
The risk factors and/or unfavorable criteria for T1 cancers
can be defined as predictive factors for positive lymph
nodes, tumor recurrence and decreased cancer-specific
survival after local excision. Many clinical and pathologi-
cal factors have been reported as risk factors. However,
most of these factors can only be identified in the resected
specimens after the resection of the tumor. Therefore, those
factors could be useful as an indication for immediate
salvage surgery or additional further treatments for local
excision.
Depth of wall invasion
The depth of wall invasion or the T stage is often reported
to be closely associated with regional lymph node metas-
tasis [6], and is one of the few factors which could be
studied preoperatively. Haggitt’s level 4 invasion into the
submucosa has been defined as a risk factor for lymph node
metastasis [33]. Suzuki et al. [35] reported that the positive
predictive value for nodal metastasis increases from 17 to
30 percent when the width (5 mm) of submucosal invasion
is added to Haggitt’s level 4. The details of the association
between the grade of invasion and regional lymph node
metastasis will be discussed in the following sections.
Tumor grade
The tumor grade has been demonstrated to be a significant
indicator for lymph node metastasis and local recurrence
[6], and is a factor that can be confirmed preoperatively.
Poorly differentiated cancer [31, 36, 37], mucinous ade-
nocarcinoma [36] and signet ring cell carcinoma [37] are
reported to be risk factors for lymph node metastasis in T1
cancer. However, the proportion of tumors showing these
histologies is low in all T1 tumors studied: 2.4 % [31], 6 %
[36] and 7.3 % of all local excision cases [37]. Nascimbeni
et al. [29] reported that poorly differentiated carcinoma
was found to be the significant predictor of lymph node
metastasis in a univariate analysis, but not in the multi-
variate model. Goldstein et al. [38] reported that the risk of
lymph node metastasis was 0 % for Grade I tumors, 20 %
for Grade II and 43 % for Grade III tumors. However, T2
tumors were included in the analysis performed for that
study.
Lymphatic and vascular invasion
Lymphovascular invasion has been reported to be a sig-
nificant factor predicting lymph node metastasis in both
univariate and multivariate analyses [29, 39–41], and
lymphatic and blood vessel invasions were identified as
independent factors predicting lymph node metastasis in
several studies [17, 42, 43]. The presence of extramural
vascular invasion [30] and vascular invasion [44] were also
independent risk factors for nodal involvement in a mul-
tivariate analysis. Kaneko et al. stated that lymphatic
involvement was a significant factor in a univariate ana-
lysis, but was not significant in a multivariate analysis [36].
Instead, the lymphatic vessel density at the site of deepest
penetration was a significant independent factor predicting
nodal involvement in the multivariate analysis, and they
proposed that the identification of lymphatic vessels by
podoplanin immunostaining provides an objective and
accurate evaluation of lymphatic involvement. Brodsky
reported that none of the T1 tumors without lymph vessel
invasion or blood vessel invasion had lymph node metas-
tasis [17].
Tumor budding or sprouting
Tumor budding is characterized by the presence of tiny
clusters of undifferentiated cells found ahead of the inva-
sive front, and is also called as sprouting [7, 37, 41, 45, 46].
Tumor budding is another significant predictor of nodal
involvement in several multivariate analyses [36, 37, 41,
44]. It might be reasonable to consider that the invasive
front of the tumor might represent characteristics of the
tumor or malignant potential. Kaneko et al. [36] showed
that the lymphatic vessel density, as described in the for-
mer section, correlated with tumor budding and the degree
of inflammation at the invasive front.
Tumor location
Several reports have shown that early carcinoma located in
the rectum has a higher rate of lymph node metastasis and/
or local recurrence [33, 34, 47, 48]. Nascimbeni et al. [29]
have indicated that the location in the rectum itself was not
a significant risk factor when compared with other colonic
segments in a study of 353 patients with sessile T1 lesions.
However, when the rectum was divided into thirds, cancer
in the lower one-third of the rectum was associated with a
significantly higher risk of lymph node metastasis.
Tumor size
Nascimbeni et al. [29] showed that the size of the carci-
nomas with nodal involvement was not significantly dif-
ferent from those without nodal involvement. In addition,
carcinomas larger than 5 cm in diameter were found to
have a higher rate of lymph node metastasis than carci-
nomas smaller than 5 cm in a univariate analysis, but not a
multivariate analysis. Goldstein et al. [38] reported that the
risk of nodal disease increased when the size was[3.5 cm,
2002 Surg Today (2014) 44:2000–2014
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although their data included the specimens with T1 and
superficial T2 tumors after abdominoperineal resection
(APR). On the other hand, Graham et al. [49] reviewed 16
published series (94 % of tumors were T1 or T2 adeno-
carcinomas with no identified regional metastases) and
identified that a tumor size greater than 3 cm was not a
significant factor predicting local recurrence or a decreased
survival. Several authors found that the size was not a
significant predictive factor for nodal involvement and/or
local recurrence [10, 17, 34, 50, 51].
Configuration or morphology
Tumors that are sessile or flat type were found to be a risk
factor for lymph node metastasis and local recurrence when
compared with pedunculated tumors in T1 cancers [34].
Nonpolypoid growth (NPG) was associated with a signifi-
cantly higher incidence of lymph node metastasis (29 %)
than polypoid growth (PG) (7 %) when the pattern of
tumor growth was classified as PG or NPG in T1 tumors
[52]. Macroscopically, type IIc and IIa ? IIc lesions were
associated with a significantly higher incidence of lymph
node metastasis (44 and 30 %) than type IIa and I lesions
(4 and 8 %) [52]. Kitajima et al. [41] clarified that the rate
of lymph node metastasis was 0 % in head invasion cases
and stalk invasion cases with a submucosal (SM) depth
\3,000 lm if the lymphatic invasion was negative for
pedunculated T1 cancer, and it was also 0 % if the sm
depth was \1,000 lm for nonpedunculated T1 tumors.
Brodsky et al. [17] showed a trend toward decreased lymph
node metastasis for sessile nonpedunculated tumors com-
pared with nonpolypoid, exophytic or ulcerated lesions
(P = 0.06) in pT1 and pT2 rectal cancers. The global
survival and local recurrence rates were significantly better
for patients with exophytic (polypoid and sessile) carci-
nomas than for those with non-exophytic (ulcerated and flat
raised) lesions after a local procedure for rectal cancer, and
the exophytic group included significantly more stage T1
and fewer T2 and T3 cancers in that report [53].
Resection margin or circumferential positive margins
Positive surgical margins, unclear margins, and unknown
or doubtful margins are not an uncommon condition after
local excision for rectal cancer. The surgical margin-posi-
tive or unclear rate varies from 4.8 to 11.1 % in T1 tumors
and from 9.8 to 22.5 % in T2 tumors, and it was 16.1 % in
T1 and T2 cancers, 1.7 % in Tis and T1 tumors and 15.5 %
in large, rectal villous adenomas based on several studies
[4, 54–57]. Many authors showed that positive surgical
margins were associated with a higher local recurrence rate
(50–100 %) after local excision, mostly for T1 and T2
tumors [6, 11, 49, 58–61]. Morson showed that the 5-year
local recurrence increased according to the grade of sur-
gical excision; from 3 % with complete excision, to 14 %
with doubtful excision and to 36 % with partial excision.
They also noted that the global survival rate decreased with
the grade of excision; which was 82 % with complete
excision, 64 % with doubtful excision and 57 % with
partial excision [61]. Graham et al. [49] reviewed a series
of local excisions for rectal cancers and concluded that
positive surgical margins were significantly associated with
increased local recurrence and decreased survival. On the
other hand, Paty et al. [11] could not demonstrate a cor-
relation of positive margins with local control in a multi-
variate analysis, although their series included the cases
with additional treatments after local excision. Positive
surgical margins or circumferential margins are not con-
sidered to be a factor associated with the tumor charac-
teristics or malignant potential, but is a factor closely
related to the techniques or procedures adopted for local
excision.
Gender
Male gender was reported as one of the significant risk
factors for lymph node metastasis of T1 cancers in the
univariate and multivariate analyses [23]. On the other
hand, female gender was a marginal risk factor (P = 0.059
and 0.076) for lymph node metastasis of T1 cancer in a
univariate analysis, but not in a multivariate analysis [40,
41]. Koide reported a significantly higher rate of nodal
involvement (P = 0.015) in female patients (21.9 %) than
in male patients (5.3 %) in a univariate analysis of 108
patients with T1 colorectal cancer [62]. However, in other
reports, gender was not confirmed as a significant predictor
of nodal involvement in patients with T1 cancers in a
multivariate analysis [31, 44].
Combinations of risk factors
Ueno et al. [37] showed that an unfavorable tumor grade,
definite vascular invasion, and tumor budding was the
combination of qualitative factors that most effectively
discriminated the risk for nodal involvement in T1 cancers,
and that the nodal involvement rate was 0.7, 20.7 and
36.4 % in the no-risk, one-risk and multiple-risk factor
groups. Koide showed that the sm invasion grade (sm1–2
and 3), lymph vessel and vascular vessel invasion and
budding were significant high risk factors for nodal
involvement, and that no cases with nodal involvement
were observed if definitive lymph vessel, vascular vessel
invasion and budding were not all confirmed, even in cases
with sm 2 and 3 invasion [62].
Therefore, the possible ‘‘risk factors’’ for rectal cancer,
which can be used preoperatively when deciding on the
Surg Today (2014) 44:2000–2014 2003
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surgical option, local therapy or radical surgery, are the
depth of invasion and tumor grade.
Lymph node metastasis in T1 cancers according
to the depth of invasion
The frequency of nodal involvement and/or metastasis in
T1 cancer according to the grade of submucosal invasion is
shown in Table 1 [25, 29, 34, 36, 39, 40, 42, 63]. The rate
of nodal involvement and/or metastasis was 0–3.2 % in
cases with a depth of invasion of sm1 or scant (corre-
sponding to sm1), and 12–25 % in sm3 or massive invasion
according to the subclassification of T1 cancer as described
in the previous section [29, 34, 42, 63]. It was 8–11 % in
cases with sm2 invasion [29, 34, 63].
In the study by Yamamoto et al. [40], sm1 was defined as
submucosal invasion up to 500 lm from the muscularis
mucosa, sm2 as submucosal invasion between 500 and
1,000 lm and sm3 as invasion beyond 1,000 lm, and the
nodal involvement rate of sm1 ? sm2 was 1.8 %. When
depth of submucosal invasion was measured, the rate of
nodal involvement was 0–1.8 % if the depth of submucosal
invasion was\1,000 lm [22, 34], and 12.8–13.8 % if it was
C1,000 lm [25, 36, 40, 41]. Sakuragi et al. [39] showed that
the nodal involvement rate was 0.7 % if the depth of
submucosal invasion was \2,000 lm, and that it was
15.5 % if it was C2,000 lm. Yasuda et al. [44] demon-
strated that there was no lymph node metastasis in T1
tumors invading \3,000 lm if no vascular invasion or
tumor budding was confirmed. Yoshida et al. [64] reported
in a study of 158 cases of T1 cancer that the depth of
invasion of all the unidentified group cases was greater than
1,000 lm when sm cancer was classified into three groups
based on the state of the muscularis mucosa (as the clearly
identified group, identified group and unidentified group).
The grade of sm massive invasion was described as one of
the criteria indicating the need for additional bowel resec-
tion due to one of the risks of nodal involvement in the
second edition of General Rules of Cancer of the Colon,
Rectum and Anus published in 1980 [65], and sm massive
invasion was defined in greater detail as deeper invasion
beyond ‘‘sm slight invasion, for example, the invasion about
200 * 300 lm’’ in the fifth edition of General Rules
published in 1994 [25, 66]. Finally, the depth of sm invasion
as one of the risk factors was extended to [1,000 lm
according to the results of accumulated case studies in the
Japanese guidelines published in 2010 [25].
According to these data, we can conclude that T1 cancer
with sm1 or submucosal invasion \1,000 lm is a ‘‘low
risk’’ cancer in terms of the nodal involvement.
Lymph node metastasis in T1 cancers according
to the previous surgery
The frequency of lymph node metastasis and lymph
vessel invasion according to the initial treatment
The frequency of nodal involvement and lymph vessel
invasion in patients undergoing radical surgery for T1
Table 1 Literature reports of lymph node metastasis in T1 tumors
according to the depth of invasion






Kodaira et al. [63] 655 sm1 3.2 Not reported
619 sm2 11.0
532 sm3 12.0
Kikuchi et al. [34] 25 sm1 0 Not reported
82 sm2 8.5
36 sm3 25.0
Tanaka et al. [42, 52] 80 sm scant 2.5 \0.01
97 sm massive 19.6
Nascimbeni et al. [29] 70 sm1 3 0.001
120 sm2 8
154 sm3 23
Sakuragi et al. [39] 141 \2,000 lm 0.7 \0.001
98 C2,000 lm 15.5
Yamamoto et al. [40] 166 sm1 ? sm2 1.8 0.0004
116 sm3 13.8
Kaneko et al. [36] 65 \1,000 lm 1.5 0.0056
203 C1,000 lm 13.8
JSCCR [25] 140 \1,000 lm 0 Not reported
672 C1,000 lm 12.8
Table 2 The frequency of lymph node metastasis and lymph vessel
invasion in patients undergoing radical surgery for T1 colorectal









Inoue et al. [67,
106]
Endoscopically 15 6.7 5.7
(n = 35a)
Surgery 35 11.4 55.3
(n = 38a)
Sawai et al. [68] Endoscopically 31 0 9.7
Surgery 51 9.8 49.0





a Based on the histological findings after the initial treatment
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cancer according to the initial treatment method is shown
in Table 2 [39, 67, 68]. The node-positive rate was
0–6.7 % in cases undergoing radical surgery after initial
endoscopic or local resection, and it was 9.8–11.4 % in
patients who had undergone initial radical surgery [39, 67,
68]. The frequency of lymph vessel invasion was
5.7–9.7 % in cases undergoing radical surgery after initial
endoscopic resection, and it was 49–55.3 % after initial
radical surgery [67, 68]. In these reports, the surgical
margin-positive rate in cases with additional surgery after
endoscopic resection was 42.9 (15/35 cases) and 51.2 (16/
31 cases) %, respectively.
Literature reports of lymph node metastasis in T1
cancer: a detailed analysis
The frequency of nodal involvement in patients undergoing
radical surgery for T1 cancer according to the cases
included is reported in Table 3 [25, 29, 31, 34, 36, 39–41,
69]. The node-positive rate widely varied from 6.3 to 20 %
in the literature. Yamamoto et al. and Sakuragi et al. [65,
66] reported frequencies of 6.3 and 7.6 %, respectively.
However, their reports included the cases after local
resection. The frequency of nodal involvement after initial
radical resection was 10.1–20 % [25, 29, 31, 34, 36, 41,
69].
As shown in this section, the frequency of nodal
involvement was lower if the patients undergoing addi-
tional radical surgery after endoscopic or local excision
were included in the reports. This might be because
additional radical surgery was performed when the surgical
margin was positive, marginal or doubtful, even when the
burn effect eliminated the residual cancer cells. Therefore,
we can conclude that the selection of the initial treatment
modality (local treatment or radical surgery), and the use of
the proper local treatment method obtaining free surgical
margins, is important. By doing this, we can eliminate
unnecessary radical surgery.
Lymph node metastasis and local recurrence after local
excision in T2 cancers
Literature reports of lymph node metastasis in T2
cancer
The literature reports of the nodal involvement rate in
patients undergoing radical surgery for T2 cancer are listed
in Table 4 [5, 17, 25, 30, 70–73]. The node-positive rate
varies from 14.5 to 25.7 % in the literature. Chok et al. [72]
discussed that the variations in the rate of lymph node
metastasis reported in the literature for intramural tumors
or early cancers are due to differences in the included
specimens (polypectomy, local excision and radical
resection), and the number of lymph nodes retrieved. The
median number of lymph nodes examined was ten (inter-
quartile range 6–14) and the node-positive rate was 14.5 %
in their study. The frequency of nodal involvement in other
reports was around 20–25 %, as shown in Table 4.
In a study to identify T2 colorectal cancer with a low
risk of nodal involvement, a poorly differentiated compo-
nent, grade II ? III, high-grade lymphovascular invasion

























Post-local resection included, n = 147
Kitajima et al.
[41]























Nash et al. [69] 145 Radical resection Rectum 20.0
JSCCR [25] 800 Radical resection Rectum 11.9























Review – Rectum 17–23
Chok et al.
[72]















JSCCR [25] 1377 Radical
resection
Rectum 25.7
Surg Today (2014) 44:2000–2014 2005
123
and a positive myxoid cancer stroma were demonstrated to
be independent risk factors for nodal involvement in a
multivariate analysis, and the incidence of nodal involve-
ment increased with the number of risk factors; with 0 risk
factors associated with a 3.8 % incidence, 1: 12.6 %, 2:
23.9 % and three factors being associated with a 48.8 %
incidence of nodal involvement [73]. However, almost all
of these factors could only be identified after local exci-
sion, and therefore can only be used to indicate the need for
additional surgery after local excision for T2 tumors.
Local recurrence after local excision for T2 cancers
Kajiwara et al. [73] recently summarized the local recur-
rence rates for T2 cancers treated with local excision, and
the local recurrence rates ranged from 19 to 47 % in cases
without adjuvant therapy and from 5 to 26 % in cases
treated with adjuvant therapy. Garcia-Aguilar et al. [8]
noted that there were similarities between the incidence of
local recurrence after the local excision of rectal cancer and
the expected incidence of lymph node metastasis, and that
suggests that tumor failure occurs in regional lymph nodes.
Preoperative biopsy and final histological findings
The tumor grade is one of the significant factors that pre-
dicts ‘‘high risk’’ T1 cancer, and is one of the key factors
used to decide on the management of early rectal cancer, as
shown in the previous section [6, 31, 36, 37]. However,
almost all of the previous reports have shown the results of
‘‘high risk’’ T1 cancers retrospectively from definitive final
histological results. Petrelli et al. [74] reported that the
biopsy specimens of rectal cancer are prone to sampling
errors, and may not be adequate for the assessment of these
histological parameters. Bretagnol et al. [6] commented
that it is important to keep in mind that some differences
exist in the grade of tumors between the initial biopsy and
the excised specimen, and cited that there was only a 30 %
accuracy when grading biopsies in Grade 1 (well-differ-
entiated) tumors reported by Takahashi et al. [75].
Pigot et al. [57] reported that colonic villous adenoma is
associated with a significant incidence of malignancy, with
foci of invasive cancer that are already present in 10-20 %
of patients at the time of diagnosis [76–79], especially in
the rectal area [77]. In their 207 consecutive patients sur-
gically treated for apparently benign villous rectal ade-
noma, nine tumors (4 %) were diagnosed as invasive
carcinoma and 28 tumors (14 %) were diagnosed as in situ
cancer based on the final histological evaluation [57].
Maeda et al. [56] reported that one ‘‘high risk’’ T1 tumor
(2 %) and 19 in situ cancers (39.6 %) were confirmed
based on the final histology among 48 tumors diagnosed as
adenoma from the initial preoperative biopsy. Haboubi
et al. [80] reported that the incidence of malignant polyps
as a proportion of all adenomas removed varies between
2.6 and 9.7 %, with an average of 4.7 %. Leslie et al. [81]
reviewed the colorectal adenomas removed by endoscopy,
and foci of malignancy were found in 0.2-8.3 % of the
cases [82–85].
On the other hand, in the villous (papillary) adenomas or
tumors diagnosed as adenoma preoperatively, T1 or inva-
sive cancers were confirmed in 35.4-51.8 % of the tumors
at the final histological evaluation [86–88]. Borschitz et al.
[89] reported that 79 patients (65.8 %) out of 120 patients
with T1 cancer based on the final histological findings
underwent surgery after the diagnosis of an adenoma. It is
well known that the frequency of cancer inclusion is
associated with the size of the villous tumors, but the depth
of invasion of villous tumors is often limited in Tis or T1
[77, 88].
Therefore, even when a preoperative biopsy shows an
adenoma, it is necessary to keep in mind that invasive or
T1 cancer might be included in the tumors, especially in
villous tumors, when deciding on the indications for local
excision.
Preoperative diagnosis of early rectal cancer
Digital rectal examination
The guidelines proposed by the American Society of Colon
and Rectum Surgeons Practice Parameters for the treatment
of rectal carcinoma recommend that proctosigmoidoscopy
should be performed in conjunction with a digital rectal
examination to determine the distance of the lesion from
the anal verge, its mobility and to assess its position in
relation to the sphincter complex as part of a full physical
examination [90]. The accuracy of the assessment of the
depth of invasion by a digital rectal examination has been
reported to vary from 58 to 88 % [6, 91–102]. However,
most of these reports included more invasive (advanced)
tumors.
The tumors within reach of digital examinations can be
characterized as mobile, tethered or fixed [102]. Patients
with large and fixed tumors can be immediately excluded
from consideration for local excision [103] because these
often show invasion into the deeper layer. Tethered tumors
often show massive invasion into the submucosal layer or
deeper [56].
Endoscopy
Endoscopy has not been included as a tool for the preop-
erative staging of early rectal cancer in most of the English
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literature [5, 6, 94, 103], but is used as a tool of complete
assessment of the colon to evaluate synchronous cancers
and polyps [90]. On the other hand, endoscopy has been
used as one of the important tools for identifying and/or
treating early rectal cancers in Japan [22, 56]. Spraying of
the abnormal mucosa with a soluble ink, such as indigo
carmine dye and control of the air transformation during
colonoscopy, as well as magnifying colonoscopy, have
been used for further evaluating early rectal cancer [7, 22,
104]. Saito et al. [105] reported the accuracy of the endo-
scopic diagnosis concerning the grade of T1 invasion to be
74.7 % (over-diagnosis rate 16.3 %, under-diagnosis rate
9.0 %). They demonstrated that the significant endoscopic
findings showing invasion beyond 1,000 lm into the sub-
mucosal layer were expansion, hardness, irregularity, an
uneven surface, fold convergence, the retraction and
hardness of the circle in protruded tumors, a protruded
lesion in a depressed lesion, an irregularity in a depressed
lesion, strong redness, no deformity after air inflation and
easy contact bleeding in superficial tumors, in addition to
the finding of protruded tumors [105].
Inoue et al. [106] evaluated the efficacy of using the
endoscopic findings after submucosal injection of 20 %
glucose for diagnosing the depth of invasion of colorectal
cancer, where the depth of invasion of the lesion lifted after
injection was defined as Tis or sm1 (slight submucosal
invasion), and that of not lifted (‘‘non-lifting sign’’) was
sm2 and more. The sensitivity, specificity and overall
accuracy were 91.2, 100 and 92.2 %, respectively, by this
method. Hurstone et al. [107] evaluated the relationship
between the invasive type V pit pattern using high-mag-
nification chromoscopic colonoscopy and the submucosal
invasion depth for flat and depressed colorectal lesions.
They concluded that the pit pattern is useful for the in vivo
staging of the depth of submucosal invasion in flat and
depressed colorectal lesions, and that it is as sensitive as
conventional 7.5 MHz EUS. However, there was a ten-
dency to overstage lesions, and hence, the technique is
limited by its low overall specificity. Nishigami et al. [108]
demonstrated the significance of the desmoplastic reaction,
which is proven by biopsy specimens, in the diagnosis of
submucosal invasion of carcinoma of the colon and rectum.
The desmoplastic reaction was not observed at the surface
of sm1 tumors, but was seen in 68 out of 70 sm2 tumors
and 74 out of 75 sm3 tumors after defining the submucosal
invasion up to 500 lm from the muscularis mucosa as sm1.
Double-contrast barium enema studies
Barium enema studies have also not been included as a tool
for the preoperative staging of early rectal cancer in the
English literature [5, 6, 94, 103], but it is useful to define
the location, circularity and extension of rectal tumors, as
well as being a tool for the complete assessment of the
colon to evaluate synchronous cancers and polyps [90].
Double-contrast barium enema studies might be useful to
identify sm massive tumors by the findings of retraction,
defects or deformity of the rectal wall [56].
Endorectal ultrasonography (ERUS)
Kwok et al. [109] reported that the accuracy of ERUS was
87 % for the T stage and 74 % for lymph node involve-
ment in a systemic review of 53 studies. Schaffzin et al.
[99, 102, 110–112] reviewed the accuracy of ERUS, and
the accuracy for the T stage varied from 62 to 93 % and
that for nodal involvement from 61 to 88 %. Bipat et al.
reported that the sensitivity for lymph node involvement
was 67 % in their meta-analysis of ERUS [113]. However,
many of these reports were based on studies of all T grades.
Garcia-Aguilar et al. reported that the accuracy of ERUS
for T1 tumors was 47 %, that for T2 tumors was 68 % and
that for T3 tumors was 70 %, and concluded that the
accuracy of ERUS was operator-dependent and varied by
tumor stage, with transmural and benign tumors the most
likely to be accurately staged [114]. Landmann et al. [115]
reported that the overall accuracy of ERUS nodal staging
for their study cohort was 70 %, with a 16 % false-positive
rate and a 14 % false-negative rate, and stated the limita-
tions of EURS in accurately staging nodal disease for early
rectal lesions.
On the other hand, the accuracy of differentiating
between T1 and more advanced cancer by ERUS has been
reported to range from 81 to 94 % [113, 116–119]. Stark
et al. [116] reported that the sensitivity of ERUS with
regard to invasive cancer was 89 %, the specificity was
88 %, the positive predictive value was 76 %, the negative
predictive value was 95 % and the accuracy was 88 %, and
among pT0 and pT1 tumors, the corresponding figures
were 80, 88, 62, 95 and 87 %. They additionally stated that
over-staging was more common in patients who had
undergone a previous excision and in tumors with peritu-
moral inflammation and desmoplastic reaction.
Concerning the diagnosis of grade of T1 cancer by
ERUS, Akasu et al. reported that the sensitivity/specificity/
overall accuracy rates for the detection of slight submu-
cosal invasion, massive submucosal invasion and muscu-
laris propria invasion were 99/74/96, 98/88/97 and 97/93/
96 %, respectively, and those for the detection of positive
nodes were 53, 77 and 72 % [120]. Santoro et al. [121]
reported that the depth of invasion was correctly deter-
mined in 87.2 % of both pT1-slight and pT1-massive
lesions using high-resolution three-dimensional ERUS, and
concluded that this method is useful for assessing the depth
of invasion in early rectal cancer and for selecting the
therapeutic options.
Surg Today (2014) 44:2000–2014 2007
123
Computed tomography (CT) and magnetic resonance
imaging (MRI)
CT and MRI of the chest and abdomen are useful tools for
identifying metastasis to the lungs and the liver [7, 102, 103].
However, the primary limitation of CT is that it cannot define
the layers of the rectal wall, and thus, cannot assess the depth
of penetration of the lesion [102]. In many reports, the accu-
racy of CT in assessing the depth of invasion and/or nodal
involvement was worse than that of ERUS [94, 102, 122, 123].
The accuracy of CT for predicting nodal involvement varies
widely, from 22 to 73 % [124]. Several authors commented on
the limitations of CT as a method of staging rectal cancer,
especially in early rectal cancers [102, 103, 125].
The accuracy rates of the T grade and nodal involve-
ment by MRI varies from 66 to 92 % and from 57 to 90 %,
respectively [98, 102, 126–128]. ERUS and MRI appear to
be equally good at assessing lymph node involvement [7,
113, 129]. In a review of 90 articles that reported on at least
20 patients with histological confirmation of the stage,
Bipat et al. [113] reported that ERUS and MRI had similar
sensitivities for T1 vs. T2 lesions, and the specificity of
ERUS (86 %) was significantly higher than that for MRI
(69 %), indicating that there was over-staging of T1 tumors
by MRI. They reported similar sensitivity (67 vs. 66 %)
and specificity (78 vs. 76 %) for the detection of nodal
disease by ERUS and MRI. However, both examinations
are highly operator-dependent [5, 113]. So far, there have
been no reports differentiating slight invasive T1 tumors
from massive invasive T1 tumors by CT or MRI.
Concerning preoperative tumor staging, Bretagnol et al.
[6] concluded that ERUS was more accurate for local
invasion, while the identification of lymph nodes remained
a major point of concern.
Current inclusion criteria for local excision in various
guidelines
The practice parameters for the management of rectal cancer
(revised) prepared by the standards practice task force of the
American Society of Colon and Rectal Surgeons (published
in 2013) recommended local excision as an appropriate
treatment modality for carefully selected patients with T1
rectal cancers without high-risk features [90]. The criteria for
local treatment include well to moderately differentiated T1
cancer, the absence of lymphovascular or perineural inva-
sion and tumors less than 3 cm in diameter occupying less
than one-third of the circumference of the bowel lumen [13,
90]. The NCCN clinical practice guidelines in oncology [13]
showed that transanal excision can be indicated for the fol-
lowing rectal cancers: \30 % circumference of the bowel,
\3 cm in size, clear margins ([3 mm), mobile, nonfixed,
within 8 cm of the anal verge, T1 and T2 (using caution in T2
due to the high local recurrence rate), endoscopically
removed polyps with cancer or indeterminate pathology, no
lymphovascular or perineural invasion, well to moderately
differentiated cancer and no evidence of lymphadenopathy
on pretreatment imaging. In addition, these guidelines
comment that when the tumor can be adequately identified in
the rectum, transanal microsurgery may be indicated.
The ESMO clinical practice guidelines show that in the
earliest, most favorable cases, chiefly the malignant polyps
[Haggitt 1–3, T1 sm1 (-2?) N0], a local procedure, e.g.,
using the transanal endoscopic microsurgery (TEM) tech-
nique, is appropriate, and that the resection should be
radical (R0), and that no sign of vessel invasion or poor
differentiation should be present [14].
The Association of Coloproctology of Great Britain and
Ireland (2012), ‘‘Federation Nationale des Centres de Lutte
contre le Cancer’’ (FNCLC, initially published 1999) and
‘‘Association Francaise de Chirurgie’’ (AFC, revised in
2005) proposed similar guidelines for local surgery, indi-
cating that local excision for a cure in rectal cancer should
be restricted to T1 tumors with well or moderate differ-
entiation and that are \3 cm in diameter [6].
An expert panel designated by the American College of
Radiology showed that the optimal candidates for a local
excision alone include small (\4 cm), low-lying T1 tumors
without adverse pathological features [130].
On the other hand, the guidelines proposed by the Japa-
nese Society for Cancer of the Colon and Rectum (JSCCR)
describe very short inclusion criteria for local excision:
preoperatively diagnosed Tis and slightly invasive T1
tumors located below the peritoneal reflection, adding that
TEM can excise more proximal tumors than conventional
local excision procedures [25]. Instead, a more detailed
description is provided for the inclusion criteria for endo-
scopic resection: preoperative diagnosed Tis and slightly
invasive T1 cancer, tumors less than 2 cm and tumors with
an undetermined morphology. In addition, these guidelines
comment that the tumor histology must be evaluated.
Expanding features, erosion, ulceration, fold convergence,
deformity and hardness of the tumors are listed as endoscopic
parameters, thus indicating the presence of massive invasive
T1 tumors in the guidelines [25, 131]. The guidelines also
recommend referencing the findings of a barium enema
study, endoscopic observation with the use of dye, high-
magnification endoscopic observation and ERUS for the
further diagnosis of the depth of invasion [25, 132–134].
Goals of local excision
Local excision for rectal cancer has many merits, because it
can eliminate defecation, sexual and urinary dysfunction,
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and can prevent the need for a permanent stoma. It is also
associated with a shorter hospital stay, and minimal mor-
tality and morbidity because it avoids radical surgery [5, 6,
9, 94, 103, 135–137]. However, the relatively high recur-
rence rate has become an issue that has hindered the further
application of the local excision of rectal cancer [7, 9]. The
local recurrence rate after local excision alone varies
widely, especially according to the T grade; from 9.7 %
(range 0–24 %) for T1 cancer, 25 (range 0–67) percent for
T2 and 38 (range 0–100) percent for T3 cancer [136]. To
assess the true merits of local excision, equivalent local
control with radical surgery has to be accomplished after
local excision for rectal cancer.
The previous reports of local recurrence after local
excision and radical surgery for T1 tumors are listed in
Table 5 [4, 9, 69, 138–146]. Although most of these studies
were retrospective studies, the local recurrence rate after
local excision for T1 cancer ranged from 0 to 24 %, and
that of radical resection from 0 to 9.9 %. In most cases,
patients who underwent local excision tended to be older
and had tumors located closer to the anal verge than those
treated by radical surgery. The overall recurrence rate after
radical resection for T1 rectal cancer was 1.1 % in the
Japanese registry [25]. The selection of the patients and
tumors, selection of the surgical procedure and the surgical
margin-positive rate are considered to be the main factors
responsible for this wide range of local recurrence after
local excision [147].
On the other hand, the local recurrence rate after radical
surgery was less than 4 % in nine out of the 12 reports
listed in Table 5. Furthermore, the nodal involvement rate
was 0–3.2 % when the depth of submucosal invasion was
slight, sm1, scant or\1,000 lm as discussed in the section
about lymph node metastasis, according to the depth of
invasion. The main difference between local excision and
radical surgery is the omission of lymph node dissection
[148], and radical surgery can excise a wide range of the
rectum without the risk of surgical margin-positive early
rectal cancer. Therefore, the goal of local excision for T1
rectal cancer as a sole curative surgery is to obtain a local
recurrence rate equivalent to that of radical surgery or a
nodal involvement rate of sm1 by selecting the proper
tumors and surgical procedure to obtain clear surgical
margins.
When is local excision indicated for ‘‘early’’ rectal
cancer?
As mentioned in the section about lymph node metastasis
and local recurrence in T2 cancer, there is currently a
limitation for the preoperative selection of ‘‘low risk’’ T2
cancers for local excision, and the nodal involvement of T2
cancers has been reported to be around 20–25 % (REFS).
Therefore, T2 cancer is not considered to be a suitable
tumor for local excision as the sole treatment method.
Furthermore, there are many reports that have shown the
limitations or undetermined effects of additional adjuvant
therapy and salvage surgery with local excision for T2
cancers and ‘‘high risk’’ T1 cancers [6, 7, 9, 69, 73, 94, 130,
136, 147, 149–151].
As shown in the section about lymph node metastasis in
T1 cancer based on the previous surgery, it is important to
select the proper treatment modality; particularly whether
local treatment or radical surgery should be performed as
the initial surgery. Detailed preoperative staging is
important for this purpose. However, the selection criteria
for ‘‘low risk’’ T1 tumors are still an issue being discussed.
Practically, the only ‘‘risk factors’’ that can be diagnosed
before surgery are the tumor grade and depth of wall
invasion, as shown in the section about the ‘‘risk factors’’
for T1 cancers. Concerning the tumor grade, differentiated
tumors should be confirmed preoperatively for their like-
lihood of being cured by local excision. However, preop-
eratively diagnosed adenoma can be considered a candidate
for local excision, as mentioned in the section about pre-
operative biopsies and the final histological findings. As
was discussed in the section describing the goals of local
excision, tumors with sm1 invasion or submucosal invasion
\1,000 lm are considered to be good candidates for local
excision as a sole curative surgery.
In this era when the diagnosis of nodal involvement is
not secure, as described in the section about the preoper-
ative diagnosis of early rectal cancer, the diagnostic tools
for determining ‘‘low risk’’ tumors with sm1 or submucosal
Table 5 Literature reports of local recurrence after local excision
and radical surgery for T1 tumors







Winde et al. [146] 24 4.1 26 0
Balani et al. [145] 7 0 17 5.9
Mellgren et al. [9] 69 18 30 0
Lee et al. [144] 52 4.1 17 0
Nascimbeni et al. [143] 70 6.6 74 2.8
Bentrem et al. [142] 151 15 168 3
Endreseth et al. [141] 256 12 35 6
You et al. [7] 601 12.5 493 6.9
Ptok et al. [140] 120 6 359 2
De Graaf et al. [139] 80 24 75 0
Nash et al. [69] 137 13.2 145 2.7
Peng et al. [138] 58 11 66 2
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invasion \1,000 lm, or for excluding ‘‘high risk’’ tumors
with sm 2–3 or submucosal invasion[1,000 lm, should be
used to select suitable tumors. Bretagnol et al. [6] con-
cluded that the selection of patients should begin with a
careful rectal examination, and that ERUS is currently the
best method for preoperatively staging early rectal tumors
to detect the depth of invasion (T stage) and lymph node
status. Maeda et al. [56] reported that the selection for local
excision was based on the findings from digital examina-
tions, double-contrast barium enema studies, proctoscopy
or colonoscopy with biopsy, as well as endoscopic ultra-
sonography, and that the selection criteria included: tumors
without poor differentiation indicated by biopsy and
tumors without ‘‘massive invasion’’ into the submucosal
layer or deeper. The following findings were considered to
indicate massive invasion: not mobile from the muscle
layer by digital examination if palpable; prominent ulcer-
ation or a ‘‘non-lifting’’ sign on proctoscopy or colonos-
copy; a retraction, defect or deformity of the rectal wall
during a barium enema study and tumor extension close to
the muscularis propria or deeper during endoscopic ultra-
sonography. These were mostly described in the section
about the preoperative diagnosis of early rectal cancer.
Thereafter, when the findings are not consistent for all
examinations with regard to the preoperative diagnosis of
the depth of invasion, local excision should be selected first
as a total biopsy [57, 61], and the histological results can be
awaited for the final diagnosis of the depth of invasion.
Otherwise, radical surgery should be performed as the
initial surgery. By following this strategy, the 12 patients
reported in the study by Maeda et al. initially underwent
radical surgery during the period studied, and 11 patients
had ‘‘high risk’’ pT1 tumors, while the remaining one
patient had Tis cancer.
We can conclude that a diagnosis excluding ‘‘high risk’’
cancers can be performed when deciding on the selection of
local excision as a sole curative surgery or whether total
biopsy should be performed. When diagnosing these cancers,
digital examinations, double-contrast barium enema studies,
proctoscopy and/or colonoscopy with biopsy and endoscopic
ultrasonography are considered to be useful tools.
Local excision is also performed for patients unfit for
major surgery because of medical comorbidities or in those
with low lesions who are adamantly seeking sphincter
preservation [149] even if tumors have ‘‘high risk’’ factors
or were more advanced. In this situation, local excision
cannot be performed as a sole curative surgery.
It is needless to say that selecting the proper local
treatment modality that can obtain free surgical margins,
and a proper histological evaluation after excision, are
important parts of performing local excision for early rectal
cancer [89].
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